An Updated Review of Cardiovascular Events in Giant Cell Arteritis
Open Access
- 15 February 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (4) , 1005
Abstract
Giant cell arteritis (GCA) is a systemic vasculitis with a direct and indirect increased risk of acute and chronic vascular events, affecting large and medium vessels, and responsible for most of the morbidity and mortality of this disease. We aimed in this review to provide an updated synthesis of knowledge regarding cardiovascular events observed in GCA. By definition, GCA patients are over 50 and often over 70 years old, and subsequently also present age-related cardiovascular risk factors. In addition, the systemic and vascular inflammation as well as glucocorticoids (GC) probably contribute to an accelerated atherosclerosis and to vascular changes leading to arterial stenoses and aortic dilations and/or dissections. GCA-related ischemic complications, especially ophthalmologic events, stroke or myocardial infarcts are mostly observed within the first months after the diagnosis, being mainly linked to the vasculitic process. Conversely, aortic complications, including dilations or dissections, generally occur several months or years after the diagnosis, mainly in patients with large-vessel vasculitis. In these patients, other factors such as atherosclerosis, GC-related endothelial damage and vascular wall remodeling/healing probably contribute to the vascular events. GCA management includes the detection and treatment of these previous and newly induced cardiovascular risk factors. Hence, the use of cardiovascular treatments (e.g., aspirin, anticoagulation, statins, anti-hypertensive treatments) should be evaluated individually. Aortic structural changes require regular morphologic evaluations, especially in patients with previous aortitis. The initial or secondary addition of immunosuppressants, especially tocilizumab, an anti-IL-6 receptor antibody, is discussed in patients with GCA-related cardiovascular complications and, more consensually, to limit GC-mediated comorbidities.Keywords
This publication has 100 references indexed in Scilit:
- Cardiovascular Disease in Cushing’s Syndrome: Heart versus VasculatureNeuroendocrinology, 2010
- Symptomatic Lower Extremity Vasculitis in Giant Cell Arteritis: A Case SeriesThe Journal of Rheumatology, 2009
- Translational Mini-Review Series on Immunology of Vascular Disease: Mechanisms of vascular inflammation and remodelling in systemic vasculitisClinical and Experimental Immunology, 2009
- Translational Mini-Review Series on Immunology of Vascular Disease: Accelerated atherosclerosis in vasculitisClinical and Experimental Immunology, 2009
- Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritisRheumatology, 2008
- Aortic involvement in recent‐onset giant cell (temporal) arteritis: A case–control prospective study using helical aortic computed tomodensitometric scanArthritis Care & Research, 2008
- Mesenteric Involvement in Giant Cell Arteritis. An Underrecognized Complication?Medicine, 2008
- Atherosclerosis in patients with biopsy‐proven giant cell arteritisArthritis Care & Research, 2007
- Low‐dose aspirin and prevention of cranial ischemic complications in giant cell arteritisArthritis & Rheumatism, 2004
- The natural history of hemispheric and brainstem infarction in Rochester, Minnesota.Stroke, 1984